Replimune Group, Inc. Faces Securities Lawsuit Alleging Fraudulent Practices

The lawsuit was filed on behalf of shareholders who suffered losses due to alleged securities fraud between November 22, 2024, and July 21, 2025. The complaint alleges that Replimune Group, Inc.'s defendants made false statements and/or concealed information about the IGNYTE trial's prospects, leading to the FDA deeming it inadequate and not well-controlled.

Key Takeaways:

• The lawsuit alleges that Replimune Group, Inc.'s defendants recklessly overstated the IGNYTE trial's prospects, given material issues that defendants knew or should have known of.
• The complaint claims that as a result, defendants' statements about Replimune's business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.
• Levi & Korsinsky LLP, the law firm representing the shareholders, has a track record of securing hundreds of millions of dollars for aggrieved shareholders.
• The firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees.
• Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States for seven years in a row.

Statistics:

• The relevant time frame for the alleged securities fraud is between November 22, 2024, and July 21, 2025.
• The lawsuit seeks to recover losses of shareholders who were adversely affected by the alleged securities fraud.
• Levi & Korsinsky LLP has secured hundreds of millions of dollars for aggrieved shareholders in past cases.
• The firm has a team of over 70 employees serving its clients.

Sources:

• Newsfile Corp., "Replimune Group, Inc. (NASDAQ: REPL) Lawsuit" (August 4, 2025)
• Levi & Korsinsky LLP, "Secure Your Rights" (August 4, 2025)
• ISS Securities Class Action Services, "Top 50 Report" (various years)